CD5/CD7 CAR-T
Cell therapy
CD5/CD7 CAR-T is one of 54 biologic programs targeting T-cell acute lymphoblastic leukemia. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
63 competitors in T-Cell Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Arranon
NovartisPhase 3
Oncovin
Eli LillyPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Purinethol
SStason
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Vepesid
AAvyxa
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD5/CD7 CAR-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Company
- EEssen Biotech